NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free POAI Stock Alerts $1.55 -0.11 (-6.63%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.8150-Day Range$1.15▼$3.7252-Week Range$1.12▼$7.12Volume88,006 shsAverage Volume30,395 shsMarket Capitalization$6.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Predictive Oncology alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Predictive Oncology Stock (NASDAQ:POAI)Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Read More POAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart POAI Stock News HeadlinesApril 25, 2024 | msn.comMiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare moversApril 25, 2024 | finance.yahoo.comFujifilm and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of BiopharmaceuticalsApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 25, 2024 | americanbankingnews.comPredictive Oncology (NASDAQ:POAI) Stock Passes Below 200 Day Moving Average of $2.93April 24, 2024 | globenewswire.comPredictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 24, 2024 | investorplace.com3 AI Penny Stocks With Massive Growth Potential: April EditionApril 23, 2024 | investing.comPredictive Oncology Inc (POAI)April 22, 2024 | finance.yahoo.comDigital Twins and Predictive Maintenance market is projected to grow at a CAGR of 46.3% by 2034: VisiongainApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 22, 2024 | finance.yahoo.comHealthcare Predictive Analytics Research Report 2024: Global Market to Reach $34 Billion by 2030, Driven by Advanced Data Tools and Value-Based CareApril 19, 2024 | msn.comPredictive Oncology, BIMI Holdings, IMAC Holdings among healthcare moversApril 17, 2024 | americanbankingnews.comPredictive Oncology (NASDAQ:POAI) Shares Cross Below 200 Day Moving Average of $3.00April 11, 2024 | finance.yahoo.comPredictive Maintenance Market Worth $47.8 billion by 2029, Growing At a CAGR of 35.1% Report by MarketsandMarkets™April 2, 2024 | finance.yahoo.comPredictive Oncology Inc. (NASDAQ:POAI) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 Predictive Oncology Inc Earnings CallMarch 31, 2024 | finance.yahoo.comPredictive Oncology Full Year 2023 Earnings: US$3.48 loss per share (vs US$7.05 loss in FY 2022)March 29, 2024 | finanznachrichten.dePredictive Maintenance Market worth $47.8 billion by 2029 - Exclusive Report by MarketsandMarketsMarch 29, 2024 | finance.yahoo.comPredictive Maintenance Market worth $47.8 billion by 2029 - Exclusive Report by MarketsandMarkets™March 29, 2024 | msn.comPredictive Oncology GAAP EPS of -$3.48, revenue of $1.78MMarch 29, 2024 | investorplace.comPOAI Stock Earnings: Predictive Oncology Reported Results for Q4 2023March 28, 2024 | globenewswire.comPredictive Oncology Reports Year End 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | finance.yahoo.comWorldQuant Predictive Appoints Amir Husain as Chairman of the BoardFebruary 24, 2024 | msn.comPredictive tests: How accurate?February 21, 2024 | finance.yahoo.comPredictive Oncology to Participate in Upcoming Investor ConferencesFebruary 21, 2024 | globenewswire.comPredictive Oncology to Participate in Upcoming Investor ConferencesFebruary 9, 2024 | msn.comPredictive Oncology Announces Chief Business Officer TransitionFebruary 3, 2024 | finance.yahoo.comGlobal Predictive Analytics Market: Forecasts Significant Growth Through 2030See More Headlines Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:POAI CUSIPN/A CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-785.62% Pretax Margin-785.62% Return on Equity-104.21% Return on Assets-70.49% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.43 Sales & Book Value Annual Sales$1.78 million Price / Sales3.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book0.81Miscellaneous Outstanding Shares4,060,000Free Float3,923,000Market Cap$6.74 million OptionableNot Optionable Beta1.28 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Raymond F. Vennare (Age 71)CEO & Chairman Comp: $525kMr. Joshua Blacher M.B.A. (Age 51)Interim Chief Financial Officer Ms. Theresa FergusonSenior Director of MarketingDr. Lawrence J. DeLucas D.ScO.D, Ph.D., Senior Vice President of BiologicsDr. Arlette H. Uihlein FCAPM.D., Senior VP of Translational Medicine & Drug Discovery and Medical DirectorKey CompetitorsHeart Test LaboratoriesNASDAQ:HSCSNanoVibronixNASDAQ:NAOVKintara TherapeuticsNASDAQ:KTRAVenus ConceptNASDAQ:VEROPaxMedicaNASDAQ:PXMDView All CompetitorsInsiders & InstitutionsCarnegie Mellon UniversityBought 10,358 shares on 2/2/2024Ownership: 0.255%Charles Lee Sr Nuzum SrSold 10,000 sharesTotal: $30,400.00 ($3.04/share)View All Insider TransactionsView All Institutional Transactions POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed in 2024? Predictive Oncology's stock was trading at $3.29 at the start of the year. Since then, POAI stock has decreased by 52.9% and is now trading at $1.55. View the best growth stocks for 2024 here. Are investors shorting Predictive Oncology? Predictive Oncology saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 13,000 shares, a decrease of 49.0% from the March 31st total of 25,500 shares. Based on an average trading volume of 29,100 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.3% of the shares of the stock are sold short. View Predictive Oncology's Short Interest. When is Predictive Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our POAI earnings forecast. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) announced its earnings results on Thursday, March, 28th. The medical instruments supplier reported ($0.85) earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $0.34 million for the quarter. Predictive Oncology had a negative net margin of 785.62% and a negative trailing twelve-month return on equity of 104.21%. When did Predictive Oncology's stock split? Predictive Oncology's stock reverse split before market open on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Platforms (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE). How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:POAI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.